Postmarketing Trials, Not Discount Cards, Promote Drug Value, Harvard's Porter Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies find themselves playing defense in debates on cost issues like reimportation because they have failed to demonstrate the value of their products, the Harvard Business School professor says. Merck's April announcement of a drug discount card program for the uninsured does not help promote value, Porter adds.